We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells Advises LabCorp on Strategic Acquisition

06 April 2011

Washington, D.C., 6 April 2011 – Hogan Lovells announced today that it is representing its long-standing client Laboratory Corporation of America Holdings (NYSE: LH) in its acquisition of Orchid Cellmark Inc. (NASDAQ: ORCH). Under the acquisition agreement, LabCorp will acquire all of the outstanding shares of Orchid Cellmark in a cash tender offer for $2.80 per share.

Laboratory Corporation of America Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing.

Orchid Cellmark is a leading international provider of DNA testing services primarily for forensic and family relationship applications.

Hogan Lovells offers international transactions capability that includes significant regulatory and business practices in Europe and the United States. Our global presence allows us to structure, negotiate, and implement highly complex cross-border transactions on behalf of our clients. The Hogan Lovells team advising LabCorp is being led by corporate partners Michael Silver, John Booher, and Richard Lewis and associates Allen Hicks, Julian Seiguer, Carin Carithers, Rod Lai, Kate Pumphrey, and Catherine Adamson; advice on regulatory issues is being provided by partners Joseph Krauss, Scott Reisch, William Neff, and T. Clark Weymouth. The Hogan Lovells team includes lawyers based in Baltimore, Washington, D.C., Silicon Valley, Denver, and London.

Loading data